**Specifications Table**TableSubject area*Biology*More specific subject area*Neuropharmacology, pain management*Type of data*Table, text file*How data was acquired*Experimental observation of nociceptive behavior in mice by using a chronometer.*Data format*Raw and analyzed*Experimental factors*Dose response curves for Single drug administration of combined drugs, given at the same of at different sites*Experimental features*Isobolographic analysis using a fixed proportion ratio of two drugs.*Data source location*N.A.*Data accessibility*Data is with this article.*

**Value of the data**--*Data tables and calculus from this article may serves as a practical guide on isobolographic analysis for testing other drug regimens of even using different pain models.*--*Determining the interaction index by isobolographic analysis provides a measure of the in vivo degree of interaction of two drugs for a specified effect.*--*Data analysis presented in this article can be systematically compared to other data from probit analysis with analgesic drugs given in combination.*

1. Data {#s0005}
=======

1.1. Summary of linear regression analyses for the agents administered alone {#s0010}
----------------------------------------------------------------------------

### 1.1.1. Intraplantar SB366791 {#s0015}

See [Table 1](#t0005){ref-type="table"}.Table 1Dose-effect data of SB366791 (i.p.) on capsaicin-induced nociception.Table 1Dosex~i~y~i~x~i~.y~i~(x~i~-$\overset{®}{X}$)^2^0.10-1.008.86-8.860.740.10-1.00-14.7714.770.740.10-1.00-41.7741.770.740.10-1.0038.29-38.290.740.10-1.0037.43-37.430.740.10-1.00-22.5722.570.740.10-1.00-23.5823.580.740.10-1.000.81-0.810.740.10-1.00-10.7610.760.740.10-1.00-0.630.630.740.10-1.00-13.8313.830.740.101.0064.31-64.310.740.10-1.0048.42-48.420.740.10-1.0018.18-18.180.740.40-0.40-13.085.230.070.40-0.40-23.219.280.070.40-0.404.64-1.860.070.40-0.409.14-3.660.070.40-0.4036.57-14.630.070.40-0.4027.14-10.860.070.40-0.4045.80-18.320.070.40-0.4033.33-13.330.070.40-0.400.27-0.110.070.40-0.4012.03-4.810.070.40-0.4059.49-23.800.071.000.00-25.750.000.021.000.0018.160.000.021.000.0012.200.000.021.000.00-1.900.000.021.000.0017.720.000.021.000.0025.320.000.021.000.002.530.000.021.000.005.060.000.021.000.00-19.610.000.021.000.006.430.000.021.000.00-12.060.000.021.000.0050.790.000.021.000.0029.370.000.021.000.0015.080.000.021.000.0044.440.000.021.000.0031.750.000.022.000.3026.587.970.192.000.3070.4621.140.192.000.3053.5916.080.192.000.3022.866.860.192.000.3040.8612.260.192.000.3013.434.030.192.000.3013.283.980.192.000.3022.496.750.192.000.3052.8515.850.192.000.30-10.13-3.040.196.000.7830.6223.890.856.000.7865.3150.940.856.000.7817.0713.320.856.000.7884.2865.740.856.000.7825.9520.240.856.000.7823.4218.270.856.000.7818.9914.810.856.000.786.334.940.856.000.7860.1346.900.85[^1][^2][^3][^4][^5][^6][^7][^8][^9][^10][^11][^12][^13]

### 1.1.2. Intraplantar Phα1β {#s0020}

See [Table 2](#t0010){ref-type="table"}.Table 2Dose-effect data Phα1β (i.p.) on capsaicin-induced nociception.Table 2Dosex~i~y~i~x~i~y~i~(x~i~−X̅)20.01-2.0019.51-39.021.000.01-2.0027.44-54.881.000.01-2.0046.34-92.681.000.01-2.000.33-0.661.000.01-2.006.23-12.461.000.01-2.00-36.3072.611.000.01-2.0020.49-40.981.000.01-2.0012.31-24.631.000.03-1.5218.90-28.730.270.03-1.5231.71-48.200.270.03-1.5218.69-28.410.270.03-1.5244.92-68.280.270.03-1.527.54-11.460.270.03-1.5230.51-46.380.270.03-1.5230.51-46.380.270.03-1.52-15.5923.700.270.10-1.0064.63-64.630.000.10-1.0026.22-26.220.000.10-1.0050.61-50.610.000.10-1.0048.17-48.170.000.10-1.008.20-8.200.000.10-1.0014.10-14.100.000.10-1.0035.74-35.740.000.10-1.0037.05-37.050.000.10-1.0025.84-25.840.000.10-1.0029.18-29.180.000.10-1.0038.53-38.530.000.30-0.5254.27-28.220.230.30-0.5244.51-23.150.230.30-0.5243.61-22.680.230.30-0.5220.00-10.400.230.30-0.5230.49-15.860.230.30-0.5245.88-23.860.230.30-0.5255.23-28.720.230.30-0.525.12-2.660.230.50-0.3067.68-20.300.490.50-0.3068.29-20.490.490.50-0.3062.20-18.660.490.50-0.3062.80-18.840.490.50-0.3065.85-19.760.490.50-0.3030.49-9.150.490.50-0.3035.08-10.520.490.50-0.3041.64-12.490.490.50-0.3041.64-12.490.490.50-0.3041.87-12.560.490.50-0.3058.57-17.570.490.50-0.3056.57-16.970.49[^14][^15][^16][^17][^18][^19][^20][^21][^22][^23][^24][^25][^26]

### 1.1.3. Intrathecal Phα1β {#s0025}

See [Table 3](#t0015){ref-type="table"}.Table 3Dose-effect data of Phα1β (i.t.) on capsaicin-induced nociception.Table 3Dosex~i~y~i~x~i~y~i~(x~i~- X̅)^2^0.0003-3.5239.54-139.202.470.0003-3.52-25.5890.052.470.0003-3.5231.40-110.502.470.0003-3.52-4.6516.372.470.0003-3.5241.29-145.302.470.0003-3.5213.11-46.152.470.0003-3.524.50-15.842.470.0003-3.52-0.983.442.470.0003-3.5213.82-48.642.470.0003-3.5212.88-45.342.470.0003-3.52-1.174.122.470.0003-3.5220.38-71.722.470.0003-2.5250.00-126.000.330.003-2.5224.63-62.060.330.003-2.5239.55-99.670.330.003-2.5234.18-86.130.330.003-2.5265.40-164.800.330.003-2.5220.37-51.330.330.003-2.5224.07-60.670.330.003-2.5217.44-43.950.330.003-2.5223.26-58.600.330.003-2.5220.93-52.740.330.003-2.5227.20-68.550.330.003-2.5263.47-159.900.330.003-2.5242.86-108.000.330.003-2.5237.24-93.840.330.01-2.0019.84-39.680.000.01-2.00-30.9561.910.000.01-2.0047.76-95.520.000.01-2.0050.00-100.000.000.01-2.0096.27-192.500.000.01-2.0040.08-80.170.000.01-2.0033.33-66.670.000.01-2.0026.58-53.160.000.01-2.0026.19-52.380.000.01-2.0041.67-83.330.000.01-2.0037.96-75.930.000.01-2.0035.19-70.370.000.01-2.0043.52-87.040.000.01-2.0043.52-87.040.000.01-2.0045.37-90.740.000.01-2.0050.00-100.000.000.10-1.0050.00-50.000.900.10-1.0036.51-36.510.900.10-1.0039.55-39.550.900.10-1.0069.40-69.400.900.10-1.0068.66-68.660.900.10-1.0029.11-29.110.900.10-1.0040.93-40.930.900.10-1.0028.27-28.270.900.10-1.0033.33-33.330.900.10-1.0058.33-58.330.900.10-1.0042.59-42.590.900.10-1.0066.67-66.670.900.10-1.0055.56-55.560.900.10-1.0059.26-59.260.900.10-1.0069.44-69.440.900.30-0.5257.14-29.712.040.30-0.52-3.972.062.040.30-0.5258.21-30.272.040.30-0.5271.64-37.252.040.30-0.5267.91-35.312.040.30-0.5245.15-23.482.040.30-0.5251.06-26.552.040.30-0.5229.96-15.582.040.30-0.5236.91-19.192.040.30-0.5260.71-31.572.040.30-0.5251.85-26.962.040.30-0.5275.93-39.482.040.30-0.5255.56-28.892.040.30-0.5262.96-32.742.040.30-0.5277.78-40.442.04[^27][^28][^29][^30][^31][^32][^33][^34][^35][^36][^37][^38][^39]

1.2. Calculation of the proportion of constituents in the mixture {#s0030}
-----------------------------------------------------------------

a + b = c. wherein:a = the quantity (in nmol) of SB366791b = quantity (nmol) of Phα1βc = sum (in nmol) of quantities of Phα1β and SB366791 in the mixture.

The proportion of a and b was fixed and calculated according to the formulae below:a = A x fb = (1-f) x B; wherein:A = DE~20~ of SB366791B = DE~20~ of Phα1βf = proportion factor.

The factor f was calculated based on the variances of the DE~20~ values from SB366791 (A) and Phα1β (B) according to the formula:f = V (B) / V (A) + V (B); wherein:V (A) = variance of DE~20~ of SB366791 andV (B) = variance of DE~20~ of Phα1β;--For combination of intraplantar Phα1β with SB366791. f = 0.38--For combination of intraplantar SB366791 with intrathecal Phα1β. f = 0.69 ([Table 4](#t0020){ref-type="table"}, [Table 5](#t0025){ref-type="table"}).Table 4Doses used in the dose-response curve for intraplantar combination of SB366791 and Phα1β.Table 4Drug pairSB366791 (nmol/site)Phα1β (nmol/site)Composed drug pair (nmol/site)10.0120.00060.01320.0370.0010.03830.110.0050.11540.330.0160.34650.990.0481.03862.970.1443.114Table 5Doses used in the dose-response curve for concurrent treatment with SB366791 (i.p.) and Phα1β (i.t.).Table 5Drug pairSB366791 (nmol/site)Phα1β (nmol/site)Composed drug pair (nmol/site)10.0220.000000480.0220004820.0660.00000140.066001430.20.00000430.200004340.600.000130.6001351.80.000391.8003965.40.001175.40117

1.3. Summary of linear regression analyses for the agents administered in combination {#s0035}
=====================================================================================

1.3.1. Phα1β (i.p.) combined with SB366791 (i.p.) {#s0040}
-------------------------------------------------

See [Table 6](#t0030){ref-type="table"}.Table 6Dose-effect data of Phα1β (i.p.) combined with SB366791 (i.p.) on capsaicin-induced nociception.Table 6Dosex~i~y~i~x~i~y~i~(x~i~−X̅)20.013-1.9234.00-64.791.570.013-1.9224.85-47.711.570.013-1.923.93-7.541.570.013-1.9227.50-52.811.570.013-1.92-19.8938.191.570.013-1.92-2.374.551.570.013-1.9232.66-62.721.570.013-1.92-63.64122.181.570.013-1.9225.00-48.001.570.013-1.9229.09-55.851.570.013-1.92-20.0038.401.570.013-1.9225.68-49.311.570.038-1.4236.81-52.270.570.038-1.4243.56-61.850.570.038-1.4226.38-37.460.570.038-1.4230.86-43.820.570.038-1.4229.27-41.570.570.038-1.4244.01-62.490.570.038-1.4226.09-37.050.570.038-1.4239.23-55.710.570.038-1.4238.14-54.160.570.038-1.4227.05-38.400.570.038-1.4220.23-28.720.570.038-1.4216.82-23.880.570.115-0.9315.95-14.830.070.115-0.9346.01-42.790.070.115-0.9327.61-25.670.070.115-0.9350.10-46.590.070.115-0.9344.09-41.000.070.115-0.9328.09-26.130.070.115-0.9332.22-29.960.070.115-0.9346.37-43.120.070.115-0.9326.09-24.270.070.115-0.9341.42-38.520.070.115-0.9337.59-34.960.070.115-0.9331.82-29.590.070.115-0.9325.00-23.250.070.115-0.9316.00-15.010.070.115-0.9316.82-15.640.070.346-0.4651.53-23.710.040.346-0.4652.15-23.990.040.346-0.4631.90-14.670.040.346-0.4654.31-24.980.040.346-0.4651.30-23.600.040.346-0.4659.12-27.190.040.346-0.4640.01-18.400.040.346-0.4633.99-15.630.040.346-0.4646.90-21.570.040.346-0.4660.04-27.620.040.346-0.4674.27-34.160.040.346-0.4635.91-16.520.040.346-0.4630.45-14.010.040.346-0.4636.59-16.830.040.346-0.4615.45-7.110.041.0380.0252.760.840.471.0380.0260.120.960.471.0380.0253.990.860.471.0380.0286.771.390.471.0380.0249.500.790.471.0380.0263.931.020.471.0380.0254.030.860.471.0380.0245.780.730.471.0380.0249.900.800.471.0380.0249.640.790.471.0380.0265.511.050.471.0380.0259.490.950.471.0380.0245.450.730.471.0380.0245.450.730.471.0380.0216.140.260.471.0380.0250.230.800.473.1140.4954.6026.751.343.1140.4963.8031.261.343.1140.4966.2632.471.343.1140.4969.9434.271.343.1140.4961.5230.151.343.1140.4965.1331.911.343.1140.4961.1029.941.343.1140.4958.7428.781.343.1140.4968.1733.401.343.1140.4967.7033.171.343.1140.4968.2533.441.343.1140.4972.0835.321.34[^40][^41][^42][^43][^44][^45][^46][^47][^48][^49][^50][^51][^52]

1.3.2. Phα1β (i.t.) combined with SB366791 (i.p.) {#s0045}
-------------------------------------------------

See [Table 7](#t0035){ref-type="table"}.Table 7Dose-effect data Phα1β (i.t.) and SB366791 (i.p.) on capsaicin-induced nociception.Table 7Dosex~i~y~i~x~i~y~i~(x~i~−X̅)20.022-1.662.00-3.071.500.022-1.66-33.7756.061.500.022-1.6632.95-54.701.500.022-1.66-34.7957.761.500.022-1.6629.24-48.541.500.022-1.6632.19-53.431.500.022-1.6649.14-81.571.500.022-1.665.42-9.001.500.022-1.6623.73-39.391.500.022-1.6637.13-61.641.500.022-1.6652.16-86.591.500.022-1.6634.40-57.101.500.066-1.1815.30-18.060.560.066-1.1851.72-61.020.560.066-1.1850.92-60.090.560.066-1.1825.35-29.910.560.066-1.18-29.9535.350.560.066-1.1834.40-40.590.560.066-1.1839.56-46.680.560.066-1.1849.14-57.990.560.066-1.1824.75-29.200.560.066-1.1832.88-38.800.560.066-1.1834.40-40.590.560.066-1.1826.88-31.720.560.200-0.6927.18-18.750.070.200-0.695.01-3.460.070.200-0.6954.88-37.870.070.200-0.6914.98-10.330.070.200-0.69-2.301.590.070.200-0.6950.23-34.660.070.200-0.6952.09-35.940.070.200-0.6946.93-32.380.070.200-0.6968.30-47.130.070.200-0.6931.86-21.990.070.200-0.6940.00-27.600.070.200-0.6959.32-40.930.070.200-0.6935.08-24.210.070.200-0.6934.00-23.730.070.200-0.6955.58-38.350.070.600-0.2262.01-13.640.050.600-0.2237.47-8.240.050.600-0.2235.88-7.890.050.600-0.2270.28-15.460.050.600-0.2254.38-11.960.050.600-0.2253.69-11.810.050.600-0.2254.30-11.950.050.600-0.2253.56-11.780.050.600-0.2265.36-14.380.050.600-0.2241.02-9.020.050.600-0.2236.95-8.130.050.600-0.2259.32-13.050.050.600-0.2252.16-11.480.050.600-0.2241.23-9.070.050.600-0.2256.95-12.530.051.8000.2581.0020.250.471.8000.2571.5017.880.471.8000.2552.5113.130.471.8000.2571.6617.910.471.8000.2557.1414.290.471.8000.2559.2214.800.471.8000.2574.2018.550.471.8000.2554.3013.570.471.8000.2567.5716.890.471.8000.2552.2013.050.471.8000.2543.0510.760.471.8000.2563.3915.850.471.8000.2544.6511.160.471.8000.2548.7512.190.471.8000.2563.7815.950.475.4000.7377.8856.851.365.4000.7357.8342.221.365.4000.7368.8950.291.365.4000.7376.4155.781.365.4000.7356.5141.251.365.4000.7369.7850.941.365.4000.7365.4247.761.365.4000.7352.2038.111.365.4000.7367.4649.241.365.4000.7357.6342.071.365.4000.7361.0544.561.365.4000.7365.1547.561.36[^53][^54][^55][^56][^57][^58][^59][^60][^61][^62][^63][^64][^65]

1.4. Statistical comparisons between experimentally obtained DE~20~ (Z~mix~) and Theoretical additive DE~20~ (Z~add~) {#s0050}
=====================================================================================================================

--***Calculation of the Z***~***add***~.--Z~add~ = f.A + (1-f). B wherein:f = the proportion factor (obtained from topic B);A = DE~20~ of SB366791;B = DE~20~ of Phα1β.--Variance of Z~add~ = f^2^. V(A) + (1-f)^2^. V(B). whereinf = proportion factor;V(A) and V(B) = Variances of the DE~20~ of SB366791 and Phα1β, respectively.--**Comparison test**--t~*critical*~ = (x-y)/\[(SEx)^2^+(SEy)^2^\]^1/2^; wherein:x = Log of Z~add~y = Log of Z~mix~(SEx)^2^ = V(Z~add~)(SEy)^2^= V(Z~mix~)--T~*tabulated*~ = \[t~add~(SEx)~2~+t~mix~(SEy)^2^\]/\[(SEx)^2^+(SEy)^2^\]; where in:t~add~ = tabular value of t based on N´-2 degrees of freedom for 95% of significancet~mix~ = tabular value of t based on N-2 degrees of freedom for 95% of significance(SEy)^2^= Variance of Z~mix~

Interpretation: If t~*critical*~\<T~*tabulated*~, then the difference is not significant, which means an additive effect. When t~*critical*~\>T~*tabulated*~, Z~*mix*~ is significantly smaller (95% of confidence) than the Z~add~, which implies a synergistic effect of combined drugs ([Table 8](#t0040){ref-type="table"}).Table 8Compilation of the comparison test.Table 8Route of combined agentsZ~add~(nMol)Z~mix~ (nMol)t~*critical*~T~*tabulated*~Statistical significanceIntraplantar/Intraplanar0.350.0256.371.96YesIntraplantar/Intrathecal0.340.0225.441.96Yes

2. Experimental design, materials and methods {#s0055}
=============================================

2.1. Capsaicin-induced nociceptive responses {#s0060}
--------------------------------------------

This test was conducted essentially as described previously [@bib1]. Briefly, individual animals were placed in transparent acrylic square boxes (20 cm per side) immediately after the capsaicin injection (1 nmol/paw i.p.), and nociceptive behaviours were recorded continuously for 300 s. Behaviours were quantified by recording the time spent licking, biting or flinching (nociceptive time) the paw injected with capsaicin. Phα1β (i.t. or i.p), SB366791 (i.p.), combined Phα1β + SB366791 or their respective vehicles were injected 10 min before the capsaicin injection. The initial dose ranges of Phα1β and SB366791 were selected based on previous data [@bib1]. Antinociceptive effects were measured as a percentage of the maximum possible (% MPE) effect according to the formula: % MPE = 100\*(A -- B / A), where A is the averaged nociceptive time of the vehicle group and B is the nociceptive time of each animal in the treated group (drugs alone or in combination) [@bib2].

2.2. Experimental design and statistical isobolographic analysis {#s0065}
----------------------------------------------------------------

Experimental design and statistical analyses were conducted essentially as previously described [@bib3], [@bib4], [@bib5]. Briefly, dose-response curves were first obtained for Phα1β and SB366791 administered alone. Line equations, slope values and respective variances were obtained using linear regression [@bib3]. DE~20~ values and 95% confidence limits were calculated using probit analysis. DE~20~ values (doses that exhibit 20% MPE) were used to assess whether the dose-effect of these drugs alone exhibited a constant potency ratio, which is necessary to perform fixed dose-pair combination of drugs [@bib4].

Drug doses in association studies were determined as a proportion of their DE~20~ values. This proportion was constant and estimated based on a factor derived from the individual variances of the DE~20~ values. This fixed proportion of agents was necessary to assess whether the combination displayed enhanced potency indicative of synergism. Dose-response curves of associated drugs were constructed to obtain the doses that achieved the same effect level (20% MPE) compared to drugs given alone. This experimentally obtained DE~20~ (here called Z~mix~) was compared to theoretically calculated DE~20~ value for additive interactions (Z~add~). The criterion for establishing a statistical significance was P \< 0.05. Graphical assessments of synergy are also presented using isobolographic analyses. Measurement of the interaction index (α) was obtained by dividing experimentally obtained DE~20~ of the drug pair by the theoretical additive DE~20~ of the drug pair. The α interaction index provides a measure of the degree of synergism.
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=============================================

Supplementary material

We thank Dr. Ronald J. Tallarida (*in memorian*) for the support on the isobolographic experimental design. We also thank for the funding agencies for supporting this work: Fapemig CBB-RED-00006-14, CNPq Universal 456048/2014, FAPEMIG Universal APQ-01553-14, Capes Toxinology 1444/2011, Capes Decit 2865/10, and INCT Medicina Molecular, CNPq 471070-2012. We thank those funds agencies for fellowship support.

Supplementary data associated with this article can be found in the online version at [doi:10.1016/j.dib.2017.07.059](http://doi:10.1016/j.dib.2017.07.059){#ir0005}.

[^1]: **Legend:** Dose (nmol/site); x~i~: Log of dose (nmol/site); y~i~: (% of MEP); x~i~y~i~: product x~i~.y~i~; (x~i~-$\overset{®}{X}$)^2^: (x~i~ -- x~i~ average)^2^.

[^2]: -Linear regression summary:

[^3]: $\sum x$= -8.38; $\sum y$= 1118.42; N= 60; $\overset{®}{X}$= -0.1397; $\overset{®}{Y}$=18.64; $\sum x$^2^ = 22.13;

[^4]: $\sum x{.y}$= 185.67; N.x.y = -156.20; $\overset{®}{X}$^2^= 0.0195

[^5]: b= $\frac{\sum\mathit{xiyi} - N\overset{®}{\mathit{xy}}}{\Sigma\mathit{xi}^{2} - N{\overset{®}{x}}^{2}}$;

[^6]: *a* = $\overset{®}{y}$ - b$\overset{®}{x}$. thus *b* = 16.3 (slope) and *a* = 20.9 *(intercept)*

[^7]: -Slope variance = ${V(b)} = \frac{s^{2}}{Ƹ\left( {\mathit{xi} - \mathit{X}} \right)2}$. wherein s^2^ = *Q/(N-2*) and *Q* = $\sum\limits_{i = 1}^{N}{(yi{–\mathit{a}–\mathit{bx}}i)}$

[^8]: V(b) = 31.3

[^9]: \- Assessment if slope differs from 0:

[^10]: t~*slope*~ = b/{V(b)}^1/2^; t~*slope*~ = 2.91 which exceeds t-tabulated, thus slope differs from zero.

[^11]: t~*table*~ (N-2 degrees of freedom; P=0.05; from [t-distribution](#t0030){ref-type="table"}) = 1.96

[^12]: \- DE~20~ calculation: DE20 = (20 -- a)/b (in log scale); DE20 = −0.056 or 0.88 nmol/site

[^13]: \- Variance of DE~20~ (V~DE20~); = s^2^ / b^2^ \[ 1/N + (x^1^−x¨)^2^/ S~xx~\]; V~DE20~ = 0.042 (in log scale)

[^14]: **Legend:** Dose (nmol/site); x~i~: Log of dose (nmol/site); y~i~: (% of MEP); x~i~y~i~: product x~i~.y~i~; (x~i~−$\overset{®}{X}$)^2^: (x~i~ --x~i~ averaged)^2^.

[^15]: Linear regression summary:

[^16]: $\sum x$= -46.92; $\sum y$= 1589.6; N= 47; $\overset{®}{X}$= -0.99; $\overset{®}{Y}$= 33.82; $\sum x$^2^ = 64.72;

[^17]: $\sum x{.y}$= -1175.24; N.x.y = -1586.9; $\overset{®}{X}$^2^= 0.99

[^18]: b= $\frac{\sum\mathit{xiyi} - N\overset{®}{\mathit{xy}}}{\Sigma\mathit{xi}^{2} - N{\overset{®}{x}}^{2}}$;

[^19]: *a* = $\overset{®}{y}$ - b$\overset{®}{x}$. thus *b* = 23.^2^ (slope) and *a* = 57.1 *(intercept)*

[^20]: Slope variance = ${V(b)} = \frac{s^{2}}{Ƹ\left( {\mathit{xi} - \mathit{X}} \right)2}$. wherein s^2^ = *Q/(N-2*) and *Q* = $\sum\limits_{i = 1}^{N}{(yi{–\mathit{a}–\mathit{bx}}i)}$

[^21]: V(b) = 18.1

[^22]: \- Assessment if slope differs from 0:

[^23]: t~*slope*~ = b/{V(b)}^1/2^; t~*slope*~ = 5.40 which exceeds t-tabulated, thus slope differs from zero

[^24]: t~*table*~ (N-2 degrees of freedom; P=0.05; from [t-distribution](#t0030){ref-type="table"}) = 1.96

[^25]: \- DE~20~ calculation: DE20 = (20 -- a)/b (in log scale); DE20 = −1.60 or 0.025 nmol/site

[^26]: \- Variance of DE~20~ (V~DE20~); = s^2^ / b^2^ \[ 1/N + (x^1^−x¨)^2^/ S~xx~\]; V~DE20~ = 0.025 (in log scale)

[^27]: Legend: Dose (nmol/site); x~i~: Log of dose (nmol/site); y~i~: (% of MEP); x~i~y~i~: product x~i~.y~i~; (x~i~−$\overset{®}{\mathbf{X}}$)^2^: (x~i~ --x~i~ averaged)^2^.

[^28]: \- Linear regression summary:

[^29]: $\sum x$= -132.32; $\sum y$= 2787; N= 72; $\overset{®}{X}$= -1.84; $\overset{®}{Y}$= 38.72; $\sum x$^2^ = 320.64;

[^30]: $\sum x{.y}$= -4120; N.x.y = -5123; $\overset{®}{X}$^2^= 3.38

[^31]: b= $\frac{\sum\mathit{xiyi} - N\overset{®}{\mathit{xy}}}{\Sigma\mathit{xi}^{2} - N{\overset{®}{x}}^{2}}$;

[^32]: *a* = $\overset{®}{y}$ - b$\overset{®}{x}$. thus *b* = 12.9 (slope) and *a* = 62.5 *(intercept)*

[^33]: \- Slope variance = ${V(b)} = \frac{s^{2}}{Ƹ\left( {\mathit{xi} - \mathit{X}} \right)2}$. wherein s^2^ = *Q/(N-2*) and *Q* = $\sum\limits_{i = 1}^{N}{(yi{–\mathit{a}–\mathit{bx}}i)}$

[^34]: V(b) = 4.9

[^35]: \- Assessment if slope differs from 0:

[^36]: t~*slope*~ = b/{V(b)}^1/2^; t~*slope*~ = 5.84 which exceeds t-tabulated, thus slope differs from zero.

[^37]: t~*table*~ (N-2 degrees of freedom; P=0.05; from [t-distribution](#t0030){ref-type="table"}) = 1.96

[^38]: \- DE~20~ calculation: DE20 = (20 -- a)/b (in log scale); DE20 = −3.28 or 0.5 pmol/site

[^39]: \- Variance of DE~20~ (V~DE20~); = s^2^ / b^2^ \[ 1/N + (x^1^−x¨)^2^/ S~xx~\]; V~DE20~ = 0.09 (in log scale)

[^40]: **Legend:** Dose (nmol/site); x~i~: Log of dose (nmol/site); y~i~: (% of MEP); x~i~y~i~: product x~i~.y~i~; (x~i~−$\overset{®}{X}$)^2^: (x~i~ --x~i~ averaged)^2^.

[^41]: \- Linear regression summary:

[^42]: $\sum x$= -54.8; $\sum y$= 3260; N= 82; $\overset{®}{X}$= 0.66822; $\overset{®}{Y}$= 40; $\sum x$^2^ = 87.4664;

[^43]: $\sum x{.y}$= -1089.7; N.x.y = -2178.55; $\overset{®}{X}$^2^= 0.446517

[^44]: b= $\frac{\sum\mathit{xiyi} - N\overset{®}{\mathit{xy}}}{\Sigma\mathit{xi}^{2} - N{\overset{®}{x}}^{2}}$;

[^45]: *a* = $\overset{®}{y}$ - b$\overset{®}{x}$. thus *b* = 21.4 (slope) and *a* = 54.1 *(intersept)*

[^46]: \- Slope variance = ${V(b)} = \frac{s^{2}}{Ƹ\left( {\mathit{xi} - \mathit{X}} \right)2}$. wherein s^2^ = *Q/(N-2*) and *Q* = $\sum\limits_{i = 1}^{N}{(yi{–\mathit{a}–\mathit{bx}}i)}$

[^47]: V(b) = 4.9

[^48]: \- Assessment if slope differs from 0:

[^49]: t~*slope*~ = b/{V(b)}^1/2^; t~*slope*~ = 9.64 which exceeds t-table, thus slope differs from zero

[^50]: t~*table*~ (N-2 degrees of freedom; P=0.05; from [t-distribution](#t0030){ref-type="table"}) = 1.96

[^51]: \- DE~20~ calculation: DE20 = (20 -- a)/b (in log scale); DE20 = −1.59 or 0.025 nmol/site

[^52]: \- Variance of DE~20~ (V~DE20~); = s^2^ / b^2^ \[ 1/N + (x^1^−x¨)^2^/ S~xx~\]; V~DE20~ = 0.016 (in log scale)

[^53]: Legend: Dose (nmol/site); x~i~: Log of dose (nmol/site); y~i~: (% of MEP); x~i~y~i~: product x~i~.y~i~; (x~i~−$\overset{®}{\mathbf{X}}$)^2^: (x~i~ --x~i~ averaged)^2^.

[^54]: \- Linear regression summary:

[^55]: $\sum x$= -35.22; $\sum y$= 3614; N=81; $\overset{®}{X}$= -0.43481; $\overset{®}{Y}$= 45; $\sum x$^2^ = 64.9758;

[^56]: $\sum x{.y}$= -573.761; N.x.y = -1571.51; $\overset{®}{X}$^2^= 0.1890

[^57]: b= $\frac{\sum\mathit{xiyi} - N\overset{®}{\mathit{xy}}}{\Sigma\mathit{xi}^{2} - N{\overset{®}{x}}^{2}}$;

[^58]: *a* = $\overset{®}{y}$ - b$\overset{®}{x}$. thus *b* = 20.1 (slope) and *a* = 53.4 *(intersept)*

[^59]: \- Slope variance = ${V(b)} = \frac{s^{2}}{Ƹ\left( {\mathit{xi} - \mathit{X}} \right)2}$. wherein s^2^ = *Q/(N-2*) and *Q* = $\sum\limits_{i = 1}^{N}{(yi{–\mathit{a}–\mathit{bx}}i)}$

[^60]: V(b) = 5.1

[^61]: \- Assessment if slope differs from 0:

[^62]: t~*slope*~ = b/{V(b)}^1/2^; t~*slope*~ = 7.99 which exceeds t-tabulated. Thus, slope differs from zero

[^63]: t~*table*~ (N-2 degrees of freedom; P=0.05; from [t-distribution](#t0030){ref-type="table"}) = 1.96

[^64]: \- DE~20~ calculation: DE20 = (20 -- a)/b (in log scale); DE20 = -1.66 or 0.022 nmol/site

[^65]: \- Variance of DE~20~ (V~DE20~); = s^2^ / b^2^ \[ 1/N + (x^1^−x¨)^2^/ S~xx~\]; V~DE20~ = 0.033 (in log scale)
